Federated Hermes
TCRX icon

Federated Hermes’s TScan Therapeutics TCRX Stock Holding History

Federated Hermes’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.9K Sell
3,982
-313
-7% -$334 ﹤0.01% 1943
2026
Q1 		$4.34K Sell
4,295
-694
-14% -$742 ﹤0.01% 1905
2025
Q4 		$4.99K Buy
4,989
+2,808
+129% +$4.06K ﹤0.01% 1893
2025
Q3 		$3.97K Hold
2,181
– – ﹤0.01% 1962
2025
Q2 		$3.16K Sell
2,181
-1
-0% -$1 ﹤0.01% 1922
2025
Q1 		$3.01K Buy
+2,182
New +$4.72K ﹤0.01% 1917
2024
Q2 		– Sell
-56
Closed -$445 – 2133
2024
Q1 		$445 Buy
+56
New +$352 ﹤0.01% 1990

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Federated Hermes's TCRX Position: Q2 2026 in Review

Federated Hermes reduced its TScan Therapeutics (TCRX) stake by 7.3% in Q2 2026, selling an estimated $334 and leaving 3,982 shares worth $3.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1943.

Federated Hermes first reported a position in TCRX in Q1 2024 and has held it in 7 quarters since. The position peaked at $4.99K in Q4 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Federated Hermes held 3,982 shares of TScan Therapeutics worth $3.9K as of Q2 2026.
  • Federated Hermes sold 313 TScan Therapeutics shares in Q2 2026, an estimated $334.
  • TScan Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1943 holding.
  • Federated Hermes first reported a position in TScan Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Federated Hermes's TScan Therapeutics position peaked at $4.99K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.